Did You Know...
...that on Dec. 15, 1836, the Patent Office was completely destroyed by fire? Lost were some 7,000 models, 9,000 drawings, and 230 books plus all records of patent applications and grants.
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7638502 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceu... | 12/29/2009 |
| 7638501 | Method of treatment of mitochondrial disorders In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such as triacetyluridine, or the like. Also provided are methods of reduc... | 12/29/2009 |
| 7622458 | Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic a... | 11/24/2009 |
| 7618950 | Method for treatment and prevention of herpes zoster by topical application A method for the treatment and prevention of herpes zoster using 5-[(E)-2-halogenovinyl] arabinofuranosyl uracil of the following general formula (1): wherein X represents a halogen atom. | 11/17/2009 |
| 7615542 | Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosp... | 11/10/2009 |
| 7608602 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions of using gemcitabine prodrugs to treat or preve... | 10/27/2009 |
| 7601702 | Dutpase Inhibitors Deoxyuridine derivatives of Formula (I′); where A is O, S or CH2; B is O, S or CHR3; R1 is H, or various substituents; R2 is H, F; R3 is H, F, OH, NH2; or R2 and R3 together fo... | 10/13/2009 |
| 7589079 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2... | 09/15/2009 |
| 7560442 | Pharmaceutically active uridine esters The present invention relates to novel uridine esters of the general formula (I) wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R′ represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a va... | 07/14/2009 |
| 7429572 | Modified fluorinated nucleoside analogues The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deo... | 09/30/2008 |
| 7419967 | Sulfonamide inhibitors of aspartyl protease The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. T... | 09/02/2008 |
| 7419968 | Methods for treating therapy-resistant tumors This invention provides methods for using novel substituted pyrimidine compounds, derivatives and analogs thereof to treat diseases such as cancer. Examples of compounds and derivatives for use in the methods are (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl L-... | 09/02/2008 |
| 7417034 | Pharmaceutically active uridine esters The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R′ represents hydrogen or a hydroxy group, thei... | 08/26/2008 |
| 7405214 | Nucleoside derivatives and therapeutic use thereof The present invention relates to nucleoside derivatives represented by general formulas I and II, their synthetic methods and their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disord... | 07/29/2008 |
| 7396826 | Pharmaceutically active uridine esters The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R′ represents hydrogen or a hydroxy group, their u... | 07/08/2008 |
| 7384924 | Modified 2′ and 3′-nucleoside prodrugs for treating infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and o... | 06/10/2008 |
| 7378401 | Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5′-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic ... | 05/27/2008 |
| 7361643 | Methods for inhibiting angiogenesis A method for inhibiting angiogenesis, including: administering a nucleoside, such as tunicamycin, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment. A method for inhibiting angiogenesis, including: administering a nucleoside, whi... | 04/22/2008 |
| 7357930 | Methods and formulations for targeting infectious agents bearing host cell proteins A formulation is disclosed for the treatment of diseases caused by an infectious agent which acquires host membranes protein during its life cycle. The formulation is a targeting pharmaceutical composition. It comprises a ligand capable of binding the host membrane ... | 04/15/2008 |
| 7348025 | Small particle liposome aerosols for delivery of anticancer drugs Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholin... | 03/25/2008 |
| 7341739 | Small particle liposome aerosols for delivery of anti-cancer drugs The small particle liposome aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes. The liposomes are administered in aqueous dispersions from a jet nebulizer to the respirato... | 03/11/2008 |
| 7323452 | Method for the accelerated in vivo removal of ethanol A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives... | 01/29/2008 |
| 7309696 | Compositions and methods for targeting cancer cells The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions o... | 12/18/2007 |
| 7304043 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereo... | 12/04/2007 |
| 7294621 | Lipid analogs for combating tumors The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7294620 | Lipid analogs for inhibiting HIV-1 activity The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7294619 | Lipid analogs for inhibiting the activity of hepatitis B antigen The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7279465 | Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases The invention relates to a method for treating infectious diseases which are elicited by viruses which are pathogenic to humans comprising the step of administering an amphiphilic nucleoside-phosphonoformic acid derivative having an esterified or unesterified carbox... | 10/09/2007 |
| 7262177 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise a naturally occurring am... | 08/28/2007 |
| 7256183 | Method for treating or preventing inflammatory diseases The present invention provides a method of preventing or treating an inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis,... | 08/14/2007 |
| 7247621 | Antiviral phosphonate compounds and methods therefor Pharmaceutical compositions comprise a nucleotide analog with a phosphonate group at a concentration effective to act as a substrate and/or inhibitor of a viral polymerase, and especially of the HCV RNA dependent RNA polymerase. ... | 07/24/2007 |
| 7244717 | Mutagenic nucleoside analogs for the treatment of viral disease The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. In particular, the invention provides 5-aldehydo-uracil nucleosides and derivatives thereof, and methods of administration thereof to increase the virus mutation r... | 07/17/2007 |
| 7238711 | Compounds and methods to inhibit or augment an inflammatory response Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided. ... | 07/03/2007 |
| 7235647 | Intermediate and process for preparing of β- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides The present invention provides a highly stereoselective, simple and economical glycosylation process for preparation of β-anomer enriched 21-deoxy-21,21-D-ribofuranosyl difluoronucleosides of formula (II), and physiologically accept... | 06/26/2007 |
| 7235583 | Fatty acid-anticancer conjugates and uses thereof The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided. ... | 06/26/2007 |
| 7229652 | Extract from the leaves of Roem., and the preparation process and uses thereof Disclosed are extracts from the leaves of Toona sinensis Roem. prepared by extracting the leaves of Toona sinensis Roem. using water and an alcohol in sequence. Also disclosed are processes for preparing extracts from the leaves of Toona sinensis | 06/12/2007 |
| 7220730 | Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer Radiolabeled conjugates are disclosed which have a component that is effective to target tumor cells, which cells selectively take up and degrade the conjugate, thereby delivering to the tumor cell nucleus a radioisotope capable of being incorporated into the nuclea... | 05/22/2007 |
| 7217770 | Stable polymeric micelle-type drug composition and method for the preparation thereof A biocompatible stable composition containing a hydrophobic drug, such as paclitaxel. The composition, which forms a syringeable polymeric micellar solution in aqueous or body fluids, is a freeze-dried product comprising a hydrophobic drug, i.e. paclitaxel, and an a... | 05/15/2007 |
| RE39573 | Antimutagenic compositions for treatment and prevention of photodamage to skin A method of improving DNA repair and reducing DNA damage and for reducing mutation frequency in skin for the purpose of reducing consequences of exposure to solar or ultraviolet radiation is disclosed. The methods comprise administering to the skin a composition con... | 04/17/2007 |